CASE Plots for the Chemotype‐Based Activity and Selectivity Analysis: A CASE Study of Cyclooxygenase Inhibitors
暂无分享,去创建一个
Jaime Pérez-Villanueva | José L Medina-Franco | Rafael Castillo | Oscar Méndez-Lucio | J. Medina-Franco | O. Méndez-Lucio | R. Castillo | Jakyung Yoo | Olivia Soria-Arteche | T. Izquierdo | Jakyung Yoo | Olivia Soria-Arteche | Teresa Izquierdo | M Concepción Lozada | J. Pérez‐Villanueva | M. Concepción Lozada
[1] Claus Schneider,et al. Cyclooxygenases and lipoxygenases in cancer , 2011, Cancer and Metastasis Reviews.
[2] Jaime Pérez-Villanueva,et al. Activity landscape modeling of PPAR ligands with dual-activity difference maps. , 2012, Bioorganic & medicinal chemistry.
[3] H. Kubinyi. QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .
[4] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[5] Mathias Wawer,et al. Navigating structure-activity landscapes. , 2009, Drug discovery today.
[6] Xi Chen,et al. The Binding Database: data management and interface design , 2002, Bioinform..
[7] José L. Medina-Franco,et al. Structure–activity relationships of benzimidazole derivatives as antiparasitic agents: Dual activity-difference (DAD) maps , 2011 .
[8] Yoo Jakyung,et al. Chemoinformatic Approaches for Inhibitors of DNA Methyltransferases: Comprehensive Characterization of Screening Libraries , 2011 .
[9] Mark Johnson,et al. Using Molecular Equivalence Numbers To Visually Explore Structural Features that Distinguish Chemical Libraries , 2002, J. Chem. Inf. Comput. Sci..
[10] W. Kiefer,et al. Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.
[11] X Chen,et al. The binding database: overview and user's guide. , 2001, Biopolymers.
[12] J. Bajorath,et al. Comparison of two- and three-dimensional activity landscape representations for different compound data sets , 2011 .
[13] Gerald M. Maggiora,et al. Hierarchical Strategy for Identifying Active Chemotype Classes in Compound Databases , 2006, Chemical biology & drug design.
[14] Austin B. Yongye,et al. Multitarget Structure-Activity Relationships Characterized by Activity-Difference Maps and Consensus Similarity Measure , 2011, J. Chem. Inf. Model..
[15] Ansgar Schuffenhauer,et al. Rule‐Based Classification of Chemical Structures by Scaffold , 2011, Molecular informatics.
[16] J. Medina-Franco,et al. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach , 2010, Molecular Diversity.
[17] I. Chessell,et al. The role of the cylooxygenase pathway in nociception and pain. , 2006, Seminars in cell & developmental biology.
[18] L. Ghibelli,et al. The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies , 2010, International journal of cell biology.
[19] Mark Johnson,et al. Algorithm for Naming Molecular Equivalence Classes Represented by Labeled Pseudographs , 2001, J. Chem. Inf. Comput. Sci..
[20] H. Kubinyi. QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .
[21] F. Ooms,et al. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. , 2000, Current medicinal chemistry.
[22] Rajarshi Guha,et al. Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..